Given the immunosuppressive function of the HGF/c-MET signaling pathway within the tumor microenvironment and the promising outcomes observed in preclinical studies targeting MET in conjunction with immunotherapy, there is a growing interest in the development of combination immunotherapies targeting MET and subsequent clinical trials. This evidence concerns the gene MET and neoplasm.